Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Prakash Radhakrishnan"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Cellular signaling pathways are intricately regulated to maintain homeostasis. During cancer progression, these mechanisms are manipulated to become harmful. O-glycosylation, a crucial post-translational modification, is one such pathway that can lea
Externí odkaz:
https://doaj.org/article/30a8c4ee4fd64eb5ac41775020b6f803
Autor:
Divya Thomas, Prakash Radhakrishnan
Publikováno v:
Molecular Cancer, Vol 18, Iss 1, Pp 1-15 (2019)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and mortality worldwide. To date, limited therapeutic achievements targeting cell proliferation and related mechanisms has led researchers to focus on the m
Externí odkaz:
https://doaj.org/article/243c12906a414132aac03c34e4c70114
Autor:
Satish Sagar, Ashok Kumar Rathinavel, William E. Lutz, Lucas R. Struble, Surender Khurana, Andy T. Schnaubelt, Nitish Kumar Mishra, Chittibabu Guda, Nicholas Y. Palermo, Mara J. Broadhurst, Tobias Hoffmann, Kenneth W. Bayles, St. Patrick M. Reid, Gloria E. O. Borgstahl, Prakash Radhakrishnan
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 2, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/1b7d921c47cb43dd8f639abebe3192bb
Autor:
Priyanka Swami, Kelly A. O’Connell, Swetha Thiyagarajan, Ayrianne Crawford, Prathamesh Patil, Prakash Radhakrishnan, Simon Shin, Thomas C. Caffrey, James Grunkemeyer, Tammi Neville, Stefan W. Vetter, Michael A. Hollingsworth, Estelle Leclerc
Publikováno v:
Biomolecules, Vol 11, Iss 4, p 526 (2021)
Pancreatic ductal adenocarcinoma (PDAC) remains a very difficult cancer to treat. Recent in vitro and in vivo studies suggest that the activation of the receptor for advanced glycation end products (RAGE) by its ligands stimulates pancreatic cancer c
Externí odkaz:
https://doaj.org/article/51680b7d1bfa4941aa1e1f8846a7af3d
Autor:
Ashley M Mohr, Jennifer M Bailey, Michelle E Lewallen, Xiang Liu, Prakash Radhakrishnan, Fang Yu, William Tapprich, Michael A Hollingsworth
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e73306 (2013)
MUC1 is a transmembrane glycoprotein that modulates transcription via its cytoplasmic domain. We evaluated the capacity of MUC1 to regulate the global transcription of microRNAs in pancreatic cancer cells expressing MUC1. Results indicated that MUC1
Externí odkaz:
https://doaj.org/article/fd50b82ee7534671b6114d0fb09ee1bd
Autor:
Prakash Radhakrishnan, Ashley M Mohr, Paul M Grandgenett, Maria M Steele, Surinder K Batra, Michael A Hollingsworth
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e73356 (2013)
Transmembrane mucins, MUC4 and MUC16 are associated with tumor progression and metastatic potential in human pancreatic adenocarcinoma. We discovered that miR-200c interacts with specific sequences within the coding sequence of MUC4 and MUC16 mRNAs,
Externí odkaz:
https://doaj.org/article/42199f1a77d74542b859e2f96f06f7bf
Autor:
Shantaram S. Joshi, Julie M. Vose, Amarnath Natarajan, Gordon L. Todd, Prakash Radhakrishnan, Ashima Shukla, Rajkumar N. Rajule, Nagendra K. Chaturvedi
PDF file - 52 KB, IC50 of 13-197 in different MCL cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fda1f90c6dd14e451ea67afc7152ea9
https://doi.org/10.1158/1535-7163.22498132.v1
https://doi.org/10.1158/1535-7163.22498132.v1
Autor:
Kamiya Mehla, Michael A. Hollingsworth, Elizabeth M. Jaffee, Jill A. Poole, Christopher F. Nicodemus, Manuel L. Penichet, Tracy R. Daniels-Wells, Ragupathy Madiyalakan, Pankaj K. Singh, Paul M. Grandgenett, Prakash Radhakrishnan, Kirsten C. Eberle, Ying Huang, Krysten E. Vance, Ayrianne J. Crawford, Daisy Gonzalez, Surendra K. Shukla, Prathamesh P. Patil, Ryan Hanson, Simon Shin, James A. Grunkemeyer, Kelly A. O'Connell, Thomas C. Caffrey, Spas Dimitrov Markov
Gating strategy for immune subsets in pancreatic tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3753305f8e07d448271a246292984a83
https://doi.org/10.1158/1535-7163.22522485
https://doi.org/10.1158/1535-7163.22522485
Autor:
Shantaram S. Joshi, Julie M. Vose, Amarnath Natarajan, Gordon L. Todd, Prakash Radhakrishnan, Ashima Shukla, Rajkumar N. Rajule, Nagendra K. Chaturvedi
Mantle cell lymphoma (MCL) is one of the most aggressive B-cell non-Hodgkin lymphomas with a median survival of approximately five years. Currently, there is no curative therapy available for refractory MCL because of relapse from therapy-resistant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b99e3e1eca9bddecb93ab75760bf19a
https://doi.org/10.1158/1535-7163.c.6535801.v1
https://doi.org/10.1158/1535-7163.c.6535801.v1
Autor:
Aaron M. Mohs, Michael A. Hollingsworth, Quan P. Ly, Prakash Radhakrishnan, Thomas C. Caffrey, Geoffrey A. Talmon, Nicholas E. Wojtynek, Madeline T. Olson
Compilation of supplemental figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2238b9c43526fd7a32bfdd4d5af0b5
https://doi.org/10.1158/1535-7163.22521153
https://doi.org/10.1158/1535-7163.22521153